Search results
8 mar 2023 · Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity ...
10 lut 2021 · In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded...
8 mar 2023 · For people with a BMI of 35 kg/m2 or more, non-diabetic hyperglycaemia and a high risk of cardiovascular disease, liraglutide alongside a reduced-calorie diet and increased physical activity is recommended in NICE's technology appraisal guidance on liraglutide for managing overweight and obesity.
HRs comparing tirzepatide with semaglutide were 1.76 (95% CI, 1.68-1.84) for 5% or greater weight loss, 2.54 (95% CI, 2.37-2.73) for 10% weighor greatert loss and 3.24 (95% CI, 2.91-3.61) for 15% or greater weight loss .
20 sie 2024 · Current guidelines recommend that individuals who have attempted lifestyle improvements and continue to have a body mass index (BMI) of ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with an obesity-related comorbidity are eligible for weight loss medication treatment.
23 cze 2024 · If 2.4 mg dose is not tolerated, participants are permitted to receive 1.7 mg instead and encouraged at least one escalation to 2.4 mg dose. ≥18 years with reported one or more unsuccessful dietary efforts to lose weight and BMI ≥27 plus at least 1 comorbidity or obesity (body mass index ≥30).
7 lip 2021 · A daily dose of 0.05–0.4 mg semaglutide (with a dose-escalation period) induced clinically relevant weight loss across all treatment groups of 6%–14% over 52 weeks (versus 2% weight loss with placebo), and was well tolerated in patients with overweight or obesity and without diabetes (n = 957) [89].
